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Abstract
Background: Hip fracture patients are heterogenous. Certain patient characteristics are associated with poorer
prognosis, but less is known about differences in response to treatment among subgroups. The Trondheim Hip
Fracture trial found beneficial effects on mobility and function from comprehensive geriatric care (CGC) compared
to traditional orthopaedic care (OC). The aim of this study was to explore differences in response to CGC among
subgroups in this trial.
Methods: Secondary analysis of the complete dataset from Trondheim Hip Fracture Trial, a randomised controlled
trial including 397 home-dwelling older adults (≥70 years) with a hip fracture. Subgroups were age (over/under
80 years), gender, fracture type (intra-/extracapsular), and pre-fracture instrumental ADL (i-ADL) (defined as over/
under 45 on the Nottingham Extended ADL scale). Dependent variables were mobility (Short Physical Performance
Battery), personal ADL (p-ADL) (Barthel Index), i-ADL (Nottingham Extended ADL scale), cognition (Mini-Mental
Status Examination), four and 12 months after hip fracture. Data were analysed by linear mixed models with
interactions (treatment, time, and subgroup), reporting treatment effects being clinically and statistically significant
within and between subgroups.
Results: Analyses within subgroups showed beneficial effects of CGC on mobility and i-ADL either at four or twelve
months in all subgroups except for males, extra-capsular fractures and patients with impaired pre-fracture i-ADL.
Beneficial effect on p- ADL was found in patients < 80 years, intra-capsular fractures and patients with impaired
pre-fracture i-ADL. Effects on cognition were found in patients < 80 years and men.
The interaction analyses showed that CGC had statistically significant better treatment effect on i-ADL for younger
participants at four months (p = 0.004), on p-ADL both at four (p = 0.037) and twelve months (p = 0.045) and
mobility at twelve months (p = 0.021), for participants with intracapsular as compared to extracapsular fractures,
and on i-ADL at twelve months for participants with higher pre-fracture function (p = 0.012).
Conclusion: Contrary to our hypothesis that the most vulnerable patients would benefit the most from CGC, we
found the intervention effect was most pronounced in younger, female participants with higher pre-fracture i-ADL
function.
Trial rigistration: ClinicalTrials.gov registration number: NCT00667914.
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Background
Hip fractures are common with more than 1.3 million
fractures annually world wide [1]. A hip fracture repre-
sents a major burden both for the individual patient and
the society [2], consequences are often reduced survival,
impaired function and problems with independent living.
Older age is associated with not regaining basic mobility
following a hip fracture. After a hip fracture mortality is
higher among men. However, there are conflicting results
on gender differences in the regaining of function [3, 4].
Several studies have reported that risk of reduced mobility
after a fracture is higher in patients with low pre-fracture
mobility and in those with extra-capsular fractures [5, 6].
Geriatric patients and hip fracture patients share features
such as high age, comorbidities, functional limitations, and
frailty [7]. Therefore, orthogeriatric treatment models where
geriatricians and orthopaedic surgeons collaborate have
been developed. As summarised in literature reviews, ortho-
geriatric treatment models have shown reduction of delir-
ium, post-surgery complication rates and mortality [8, 9],
and improved mobility [10]. A recent paper from The
Trondheim Hip Fracture Trial reported that treatment of
home-dwelling hip-fracture patients with comprehensive
geriatric care (CGC) throughout the entire hospital stay
gave statistically significant and clinically meaningful better
mobility, personal activities of daily living (p-ADL), instru-
mental ADL (i-ADL), and cognition, and was also cost-
effective as compared to traditional care [11].
Previous studies indicate beneficial effects of compre-
hensive geriatric care (CGC) for hip-fracture patients in
general [11, 12], but less is known about benefits of CGC
in targeted subgroups. Although a number of prognostic
factors for functional outcomes are relatively well known,
we have not found any randomised controlled trial (RCT)
evaluating treatment effects of CGC versus traditional
orthopaedic care (OC) related to subgroup characteristics.
When planning for The Trondheim Hip-Fracture
Trial, we hypothesised that benefits of a comprehensive
and individualised orthogeriatric treatment programme
were independent of age, gender and fracture type, and
that focusing on functional recovery in the CGC group
would especially benefit those with more severe pre-
fracture impairments.
The aim of the present study is to explore post hoc if
treatment effects of CGC as compared to OC depend on
subgroups defined by age, gender, type of fracture or
pre-fracture function. This will be studied separately for
the outcome measures of mobility, p-ADL, i-ADL, and
cognition.
Methods
Trial design and patients
The Trondheim Hip-fracture Trial is a prospective RCT
recruited patients at St. Olav University Hospital in
Trondheim, Norway between April 2008 and December
2010, last follow-up assessment was completed January
2012. The protocol, the intervention and clinical outcomes
from the study have been published previously [11, 13–15].
Home-dwelling patients 70 years or older who had been
able to walk 10 m prior to the hip-fracture were eligible.
Patients with pathological fractures, multiple trauma, short
life expectancy, living permanently in a nursing home, or
already participating in the study were excluded. A nurse
in the emergency room screened the patients for eligibility,
collected informed written consent by either the patients
or their next of kin, and randomised the patients. A
web-based computer-generated service prepared by the
Norwegian University of Science and Technology (NTNU)
was used that randomised patients in a ratio of 1:1 and
blocks of unknown size was used. Patients were rando-
mised to receive CGC or OC and were transferred to the
allocated wards directly after randomisation. Blinding of
patients and staff was not possible, while assessors were
partly blinded during follow-up [11]. Patient flow is shown
in Fig. 1.
Treatment
As described previously [14] patients in both groups re-
ceived the same perioperative treatment. In most pa-
tients surgery was performed in spinal anaesthesia.
Arthroplasty was used for dislocated intracapsular frac-
tures (Garden type 3 or 4) while Garden type 1 or 2 frac-
tures were mainly treated with a two-screw fixation. A
sliding hip screw system was used for extracapsular frac-
tures except for some sub trochanteric fractures that
were treated with intramedullary nailing. Most patients
were allowed full weight-bearing postoperatively, except
for 17 (9 %) and 20 (10 %) in the CGC and OC groups
respectively, who got restrictions. Most of these had sub-
trochanteric fractures or other fractures that were consid-
ered to be unstable according to the fixation method and
reposition, or the surgeon had judged the bone as too
osteoporotic for weight-bearing even after fixation.
In the orthopaedic trauma ward OC patients received
treatment according to national and international guide-
lines [16–18]. In the geriatric ward patients were treated
pre- and postoperatively using CGC performed as a
multidimensional interdisciplinary diagnostic process fo-
cusing on the patients’ medical, mental, social and func-
tional situation. The CGC emphasised medical assessment
including review of drug regimen, pain relief, hydration,
nutrition, elimination, and assessment of fall risk and
osteoporosis. In addition the interdisciplinary team fo-
cused on early mobilisation and rehabilitation and early
individualised discharge planning.
The primary health care services were responsible for
follow-up after discharge from hospital in both groups.
Neither group was routinely offered hospital-based
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follow-up, except for selected patients who were offered
follow-up in the orthopaedic outpatient clinic as decided
by the orthopaedic surgeons. We developed an integrated
plan for treatment and follow-up for each patient [14].
Measurements
P-ADL and i-ADL before the fracture and at four and
12 months were assessed by the Barthel Index (BI; 0 to
20 points; 20 best score) and the Nottingham Extended
ADL Scale (NEAS; 0–66 points; 66 best score) [19, 20].
The median pre-fracture NEAS score was 45, and pa-
tients with NEAS scores ≥45 before the fracture were
regarded well-functioning, while those with scores < 45
were regarded impaired in i-ADL. Data were obtained
by interviewing the patient or, if he/she was not able to
respond, their next of kin. Mobility at four and
12 months was assessed by the Short Physical Perform-
ance Battery (SPPB; 0 to 12 points; 12 best score) [21].
Cognition was assessed by the Mini Mental Status Exam-
ination (MMSE; 0–30 points; 30 best score) [22]. The
American Society of Anaesthesiologists (ASA) score [23]
was used as preoperative risk score. Medical information
was collected from hospital records.
Statistical analysis
Sample size was calculated for the analysis of the main
effect (without subgroups). For an estimated effect size
of 1.0 point in mean SPPB score at four months after
surgery, and with an α level of 0.05 304 patients were
needed for 80 % power. To allow for an estimated 20 %
drop-out rate 380 patients were required, in the end a
total of 397 were included. Sample size estimations were
Excluded (n=680)
- Not meeting inclusion 
criteria (n=559)
- Declined participation (n=54)
- Other reasons (n=67)
Assessed for eligibility
(n=1077)
Randomized
(n=397)
Allocated to CGC (n=198)
Received CGC (n=197)
Received OC (n=1)
Allocated to OC (n=199)
Received OC (n=198)
Received CGC (n=1)
4 months
Remaining participants (n=174)
Deceased (n= 19)
Withdrawn (n= 5)
Analysed (n= 165)
4 months
Remaining participants (n=170)
Deceased (n= 21)
Withdrawn (n= 8)
Analysed (n=160)
12 months
Remaining participants (n=162)
Deceased (n=30)
Withdrawn (n=6)
Analysed (n= 151)
12 months
Remaining participants (n=149)
Deceased (n= 37)
Withdrawn (n=13)
Analysed (n=133)
Fig. 1 Patient flow chart. CGC = Comprehensive Geriatric Care; OC = Orthopedic Care
Prestmo et al. BMC Geriatrics  (2016) 16:49 Page 3 of 10
not carried out for the post hoc analyses. There were no
planned or unplanned formal interim analyses. An inde-
pendent clinical trials unit reviewed emerging safety data
(mortality and serious adverse events), and the assump-
tions underlying the sample size calculation when 200
patients had been recruited [11].
The statistical analysis plan that was completed before
performing any data analysis, also involved subgroup ana-
lyses regarding pre-fracture function. Subgroup analyses
on age, gender and fracture type were decided posthoc.
Differences between subgroups were analysed by linear
mixed models with interactions between treatment, time,
and subgroup, using SPPB, BI, NEAS, and MMSE as
dependent variables. Independent variables were time,
group allocation (CGC vs OC), and age (70 to 79 vs
≥80 years), gender, fracture type (intra- vs extra-
capsular) and pre-fracture function (median NEAS < 45
vs ≥45). An interaction between the subgroup and the
treatment effect implies a three-way interaction (be-
tween time, treatment and subgroup). The magnitude of
the three-way interaction is not of practical interest, but
the interest lies in the effect of treatment group at four
and 12 months. Hence, at each time point, we report the
treatment effect within subgroups, and the difference in
treatment effect between subgroups.
The results within and between subgroups are presented
as mean scores for differences with 95 % Confidence In-
tervals (CI). Differences in treatment effect between sub-
groups are reported with CIs and p-values for the relevant
two-way interactions. Two-sided p-values <0.05 were con-
sidered statistically significant. For evaluation of whether
test score differences are clinically meaningful previously
reported reference values were used: SPPB ≥ 0.5 points
[24], BI ≥ 1.4 points [25], NEAS ≥ 2.4 points [26], and
MMSE ≥ 2 points [27].
Analyses were performed using SPSS 21.
Ethics
The study was approved by the Regional Committee of
Ethics in Medical Research (REK4.2008.335), the Norwe-
gian Social Science Data Services (NSD19109) and the
Norwegian Directorate of Health (08/5814). Clinical-
Trials.Gov registry number was NCT00667914.
Results
Baseline characteristics
As shown in Fig. 1 a total of 1077 patients were screened
for eligibility, of these 559 did not meet inclusion cri-
teria, 54 declined participation and 67 were not included
from other reasons, while 397 were randomised 198 to
CGC and 199 to OC.
The two groups were comparable regarding baseline
characteristics (Table 1). Mean age was 83 years, three of
four patients were female, and 60 % were living alone.
More than 50 % in both groups had an ASA score of 3
or higher. About 60 % had intra-capsular fractures, of
whom 76 (63.9 %) in the CGC and 89 (69.3 %) in the
OC were operated with arthroplasty (Table 1) (p = 0.37).
Baseline characteristics for each subgroup has been
added as Additional file 1.
Clinically meaningful treatment effects of CGC versus OC
within subgroups
Table 2 and Fig. 2 show that at four months patients
aged 70–79 years treated with CGC had better perform-
ance on SPPB, BI and NEAS than patients treated with
OC, and at 12 months better performance on NEAS
and MMSE. CGC patients ≥80 years of age had better
Table 1 Baseline characteristics
Geriatric Orthopaedic
n = 198 n = 199
Age (years) - mean (SD) 83.4 (5.4) 83.2 (6.4)
Sex (female) - n (%) 145 (73.2) 148 (74.4)
Sheltered housing - n (%) 26 (13.5) 20 (10.3)
Living alone - n (%) 115 (58.1) 124 (62.3)
Barthel Index (0–20) - mean (SD) 18.3 (2.3) 18.1 (2.8)
NEAS (0–66) - mean (SD) 42.5 (17.7) 41.9 (17.5)
ASA score (1–5) mean (SD) 2.5 (0.7) 2.6 (0.7)
ASA score
1 or 2 (healthy or mild systemic
disease) - n (%)
89 (45.0) 82 (41.2)
3 (severe systemic disease) - n (%) 103 (52.0) 106 (53.3)
4 or 5 (severe systemic disease
or moribund) - n (%)
6 (3.0) 11 (5.5)
Previous diagnoses
Heart disease - n (%) 97 (49.0) 89 (44.7)
Stroke - n (%) 49 (24.7) 57 (28.6)
Diabetes - n (%) 23 (11.6) 28 (14.1)
Dementia - n (%) 27 (13.6) 26 (13.1)
Cancer - n (%) 53 (26.8) 43 (21.6)
Kidney disease - n (%) 18 (9.1) 9 (4.5)
Fracture type
Femoral neck - n (%) 119 (60.1) 127 (63.8)
Extra capsular fracture- n (%) 79 (39.9) 72 (36.1)
Surgery
Hemi prosthesis - n (%) 76 (38.4) 88 (44.2)
Bone plates and -screws - n (%) 69 (34.8) 63 (31.7)
Screws – n (%) 38 (19.2) 32 (16.1)
Othera- n (%) 15 (7.6) 16 (8.0)
ASA American Society of Anaesthesiologists
aIncluding patients treated with combinations of surgery or no surgery at all
due to death
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Table 2 Results of linear mixed model analysis
CGC OC CGC OC 2-way interaction
(mean) (mean) GD (95 % CI) p-value (mean) (mean) GD (95 % CI) p-value GD (95 % CI) p-value
4 months (n = 325)
Age 70–79 (n = 98) Age 80 or older (n = 227)
SPPB 6.41 5.32 1.09 (0.19–1.99) 0.017 4.53 3.91 0.62 (0.03–1.20) 0.039 0.47 (−0.60 to 1.55) 0.39
Barthel 17.19 15.27 1.92 (0.66–3.18) 0.003 16.05 15.49 0.56 (−0.26–1.37) 0.18 1.36 (−0.14 to 2.86) 0.08
NEAS 39.18 27.73 11.44 (6.54–16.35) <0.0001 30.30 27.36 2.94 (−0.25 to 6.13) 0.07 8.50 (2.65–14.35) 0.004
MMSE 25.64 23.66 1.97 (−0.06–4.02) 0.06 23.02 22.33 0.70 (−0.62–2.02) 0.30 1.28 (−1.14–3.71) 0.30
Male (n = 78) Female (n = 247)
SPPB 5.09 5.03 0.06 (−0.93–1.05) 0.91 5.07 4.14 0.94 (0.37–1.50) 0.001 0.88 (−0.26–2.02) 0.13
Barthel 15.94 15.60 0.34 (−1.03–1.72) 0.63 16.51 15.36 1.15 (0.36–1.94) 0.005 0.81 (−0.78–2.40) 0.32
NEAS 30.43 27.13 3.30 (−2.08–8.68) 0.23 33.60 27.58 6.02 (2.93–9.12) 0.0001 2.72 (−3.48–8.93) 0.39
MMSE 23.75 22.64 1.11 (−1.13–3.34) 0.33 23.79 22.78 1.01 (−0.27–2.29) 0.12 0.09 (−2.48–2.67) 0.94
Intra-capsular fracture (n = 203) Extra-Capsular fracture (n = 122)
SPPB 5.61 4.54 1.07 (0.46–1.69) 0.001 4.21 4.07 0.14 (−0.66–0.94) 0.73 0.93 (−0.08–1.95) 0.07
Barthel 17.00 15.47 1.53 (0.66–2.39) 0.001 15.40 15.38 0.02 (−1.10–1.14) 0.97 1.51 (0.09–2.92) 0.037
NEAS 35.02 28.16 6.85 (3.48–10.23) 0.0001 29.35 26.40 2.94 (−1.45–7.34) 0.19 3.91 (−1.64–9.45) 0.17
MMSE 24.01 22.62 1.39 (−0.01–2.80) 0.05 23.47 22.97 0.50 (−1.30–2.30) 0.59 0.90 (−1.39–3.19) 0.44
Pre-fracture NEAS≥ 45 (n = 178) Pre-fracture NEAS < 45 (n = 147)
SPPB 6.59 5.66 0.93 (0.28–1.59) 0.005 3.22 2.78 0.45 (−0.26–1.15) 0.22 0.49 (0.48–1.45) 0.32
Barthel 18.36 17.83 0.53 (−0.40–1.47) 0.27 14.06 12.64 1.42 (0.42–2.42) 0.005 0.89 (−0.48–2.26) 0.20
NEAS 44.77 37.44 7.34 (3.83–10.84) <0.0001 19.06 16.03 3.03 (−0.73–6.78) 0.11 4.31 (−0.82–9.45) 0.10
MMSE 26.44 25.01 1.43 (−0.08–2.94) 0.06 20.51 19.88 0.62 (−1.01–2.25) 0.45 0.80 (−1.42–3.03) 0.48
12 months (n = 284)
Age 70–79 (n = 87) Age 80 or older (n = 197)
SPPB 6.48 5.64 0.84 (−0.09–1.78) 0.08 4.63 3.93 0.70 (0.08–1.31) 0.027 0.14 (−0.98–1.26) 0.80
Barthel 17.34 16.29 1.05 (−0.24–2.35) 0.11 16.20 15.09 1.11 (0.26–1.95) 0.011 0.05 (−1.49–1.60) 0.95
NEAS 39.01 31.33 7.68 (2.62–12.64) 0.003 31.75 26.63 5.12 (1.79–8.45) 0.003 2.56 (−3.50–8.62) 0.41
MMSE 25.13 22.90 2.23 (0.16–4.30) 0.035 23.00 21.92 1.07 (−0.27–2.42) 0.12 1.16 (−1.31–3.63) 0.36
Male (n = 65) Female (n = 219)
SPPB 5.33 5.47 −0.14 (−1.20–0.91) 0.79 5.13 4.17 0.96 (0.37–1.55) 0.001 1.10 (−0.11–2.31) 0.07
Barthel 16.25 15.78 0.47 (−0.99–1.93) 0.53 16.62 15.38 1.24 (0.42–2.06) 0.003 0.77 (−0.90–2.44) 0.37
NEAS 33.07 27.78 5.29 (−0.47–11.04) 0.07 34.10 28.21 5.89 (2.69–9.08) 0.0003 0.60 (−5.98–7.19) 0.86
MMSE 23.95 21.36 2.59 (0.30–4.87) 0.027 23.50 22.49 1.01 (−0.29–2.31) 0.13 1.58 (−1.05–4.01) 0.24
Intra-capsular fracture (n = 177) Extra-Capsular fracture (n = 107)
SPPB 5.61 4.42 1.19 (0.54–1.84) 0.0003 4.45 4.51 −0.06 (−0.090–0.78) 0.89 1.25 (0.19–2.31) 0.021
Barthel 16.95 15.33 1.62 (0.72–2.52) 0.0004 15.85 15.72 0.13 (−1.02–1.27) 0.83 1.49 (0.04–2.95) 0.045
NEAS 35.15 28.76 6.40 (2.86–9.83) 0.0004 31.66 27.05 4.61 (0.11–9.11) 0.045 1.79 (−3.94–7.51) 0.54
MMSE 22.94 22.37 1.14 (−0.29–2.58) 0.12 23.77 22.00 1.77 (−0.06–3.61) 0.06 0.63 (−1.70–2.96) 0.60
Pre-fracture NEAS≥ 45 (n = 164) Pre-fracture NEAS < 45 (n = 120)
SPPB 6.81 5.98 0.83 (0.16–1.51) 0.016 3.06 2.57 0.49 (−0.26–1.24) 0.20 0.34 (−0.67–1.35) 0.51
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SPPB scores at four and 12 months, and better NEAS
score at 12 months than the OC patients.
In females there were clinically meaningful treatment
effects in favour of CGC for SPPB and NEAS at four
and 12 months. For men the MMSE scores for the CGC
group was better at 12 months, but there were no other
statistically significant differences at four or 12 months.
At four and 12 months patients with intra-capsular
fractures treated with CGC had better scores on SPPB,
BI and NEAS. Patients with extra-capsular fractures had
a better treatment effect of CGC than OC only for
NEAS at 12 months.
CGC patients with pre-fracture NEAS ≥45 had better
scores on SPPB and NEAS at four and 12 months and
better MMSE scores at 12 months. Among patients with
pre-fracture NEAS <45 there was better scores for BI at
four months and no statistically significant differences
between the CGC and OC group at 12 months.
Clinically meaningful treatment effects of CGC versus OC
between subgroups
The analysis showed that CGC was better than OC for pa-
tients 70–79 years of age as compared to patients ≥80 years
for NEAS at four months, while there were no differences
at 12 months. In patients with intra-capsular as compared
to extra-capsular fractures, CGC was better for BI at four
and 12 months and for SPPB at 12 months. In patients
with pre-fracture NEAS ≥45 as compared to NEAS < 45,
CGC was better for NEAS at 12 months (Table 2).
Discussion
We have previously reported that treating home-
dwelling hip-fracture patients in an orthogeriatric ward
improves mobility, p-ADL, i-ADL and cognition more
than treating patients in an orthopaedic ward. Our over-
all aim of the present study was to explore treatment ef-
fects on functional measures between subgroups of the
hip-fracture population. This post hoc study have shown
that home-dwelling hip-fracture patients irrespective of
age, gender, type of fracture or pre-fracture function
have better effect of CGC than OC in one or more func-
tional outcomes, and that these group differences are of
clinical importance. Nevertheless, the results demon-
strated only minor differences in functional outcomes
between the CGC and OC group among men, patients
with extracapsular fractures, and those with impaired i-
ADL before the fracture. The interaction analyses showed
that CGC had statistically significant better treatment effect
on i-ADL for younger participants at four months (p =
0.004), on p-ADL both at four (p = 0.037) and twelve
months (p = 0.045) and mobility at twelve months (p =
0.021), for participants with intracapsular fractures as com-
pared to extracapsular fractures, and on i-ADL at twelve
months for participants with higher pre-fracture function
(p = 0.012).
We have not found other publications studying if ef-
fects of orthogeriatric care differ in subgroups of pa-
tients. However, our overall results indicating somewhat
better effects of CGC than OC irrespective of subgroup
are in line with a Cochrane review on comparison of
comprehensive geriatric assessment with general medical
care in hospitalised acutely sick elderly patients, that
showed that the benefits were related to treatment in a
geriatric ward per se and not a consequence of admis-
sion criteria like age and other factors [28].
Previous studies have shown that older patients have
poorer functional recovery than younger patients after
hip-fractures [29]. In the present study there were statis-
tically and/or clinically meaningful differences between
the CGC and OC groups independent of age group. For
patients ≥ 80 years the effect of CGC was more pro-
nounced at 12 months. The between-subgroup analysis
showed a significant better effect of CGC on i-ADL at
four months in patients 70–79 years as compared to pa-
tients ≥80. This difference between age groups disap-
pears after one year where the superior effect of CGC is
fairly similar regardless of age. The change is mainly due
to improved i-ADL in the older group by CGC, but not
in OC. Our interpretation is that patients ≥80 need more
time to improve, and that the effect of CGC may persist
beyond discharge due to a better definition of treatment
goals, better discharge planning or a better individual
plan for rehabilitation.
Arinzon & al [30] have previously found that both
men and women improve mobility during hip-fracture
rehabilitation, while other studies have found better
prognosis for female hip-fracture patients [31]. In our
study we found that while female CGC patients had
Table 2 Results of linear mixed model analysis (Continued)
Barthel 18.74 17.68 1.05 (0.10–2.01) 0.031 13.89 12.88 1.01 (−0.04–2.06) 0.06 0.05 (−1.37–1.47) 0.95
NEAS 47.11 38.38 8.73 (5.14–12.32) <0.0001 18.08 16.18 1.90 (−2.06–5.85) 0.35 6.83 (1.48–12.17) 0.012
MMSE 26.33 24.42 1.91 (0.38–3.44) 0.015 20.24 19.47 0.77 (−0.91–2.45) 0.37 1.14 (−1.14–3.41) 0.33
The two-way interaction term GD is the difference in effect of CGC vs OC between the subgroups, for example 1.09–0.62 = 0.47 for SPPB, age70-79 vs age
80+, 4 months
CGC Comprehensive Geriatric Care, OC orthopaedic care, GD Group difference, SPPB Short Physical Performance Battery, Barthel Barthel Index, NEAS Nottingham
Extended ADL Scale, MMSE Mini Mental Status Examination
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statistically and clinically significant better mobility and
i-ADL at four and 12 months, the only effect for male
CGC patients was on better cognition at 12 months.
This is in line with the findings in our main publication
from the study where we found improved cognition at
12 months in the CGC group [11]. All outcomes in the
Fig. 2 Results of mixed model analysis: Estimated outcome in each subgroup and treatment, with 95 % confidence interval. P-values are reported
for interaction between subgroup and treatment. For example, p = 0.004 for age and NEAS at 4 months: The treatment effect (difference in NEAS)
for patients aged < 80 is significantly larger than the difference for patients aged≥ 80
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present study measure different aspects of function.
Cognitive impairment is frequently shown among sick,
frail elderly patients and often interrelated with general
health status [32]. Nevertheless, we have no plausible
explanation for the gender difference found in the
subgroup analyses. Still, there was no significant effect
of gender in the between-group analyses, possibly due
to lack of statistical power. Further research particu-
larly designed to assess gender effects of rehabilitation
is warranted in order to improve treatment outcomes
particularly in male hip-fracture patients.
Better effect in favour of CGC on the intra-capsular
fracture group was found at both four and 12 months,
while for the extra-capsular fracture group there was
only a rather small effect on i-ADL at four and
12 months. The interaction analyses confirmed these
findings by revealing increased benefit of CGC versus
OC on several outcomes for intra-capsular as compared
to extra-capsular fractures. Our findings also support
previous studies showing that in general prognosis is
poorer for extra-capsular as compared to intra-capsular
fractures [33]. One explanation may be that these pa-
tients have a larger trauma with more soft tissue damage
and needing more extensive surgery. Further research is
needed in order to improve the outcome for this patient
group.
When planning the study we hypothesised that pa-
tients with high pre-fracture i-ADL scores would benefit
least from CGC, and the group with impairments in i-
ADL before the fracture would benefit the most. We
found however a marginal effect on p-ADL at four
months and no effect on other outcomes for the group
with low pre-fracture i-ADL scores, while CGC im-
proved mobility and i-ADL at four and 12 months for
the group with high pre-fracture i-ADL scores. Thus,
our hypothesis was not supported. The interaction
analysis showed that CGC was significantly better for
patients with high pre-fracture i-ADL scores than for
those having low pre-fracture i-ADL scores on i-
ADLduring follow-up. This is in line with findings
from the The Oslo Orthogeriatric Trial that also
showed beneficial effect on mobility among those be-
ing fittest before the fracture [34]. The median NEAS
score was only 45 at baseline, indicating that most
participants actually had a functional decline before
the fracture. Thus, our findings support previous stud-
ies reporting that impaired pre-fracture function ap-
pears to be a consistent predictor of unfavourable
outcomes and not regaining mobility in older persons
with hip-fractures. [5, 6, 29, 33, 35].
The strengths of the study are the randomised con-
trolled design and large sample size, and that we had a
plan for analysis of subgroup effects based on pre-
fracture function before the study started. The main
weakness is the post-hoc design with choice of the other
subgroups based upon literature review (defined after
the main outcomes of the study were known). We have
found no consensus on how to categorise patients with
impaired function before the fracture. As there was a
ceiling effect of BI before the fracture with a median
score of 20 while the median NEAS score was 45 of 66
points, we selected pre-fracture NEAS to categorise
pre-fracture function. In lack of established cut-off
values for the NEAS we dichotomised by the median of
the baseline score. Other weaknesses are lack of power
for some subgroups, and that a large number of ana-
lyses have been performed increasing the chance of
Type I error. However, according to the viewpoints of
Rothman, we have not adjusted for multiple testing
[36, 37]. The outcome measures in this study were
chosen to represent aspects of function, while subject-
ive reported outcomes as for example quality of life
were not studied. Thus, conclusions should not be gen-
eralised to other domains. The study was exploratory,
and further studies primarily designed to study effect
of treatment on subgroups have to be undertaken to
confirm findings.
Conclusion
Our main results were that in home-dwelling hip-
fracture patients all subgroups of patients benefit of
CGC on one or more functions (mobility, i- and p-ADL,
and cognition), irrespective of age, gender, type of frac-
ture and pre-fracture function. These findings support
the implementation of CGC for different subgroups of
home-dwelling hip-fracture patients. Contrary to our hy-
pothesis that the most vulnerable patients would benefit
the most from CGC, we found the intervention effect
was most pronounced in younger, female participants
with higher pre-fracture i-ADL function. Our results
also show that there is need of further research, espe-
cially on extra-capsular fractures, on males, and patients
with functional decline before the fracture.
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